LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase

Current Opinion in Lipidology

Volumn 25, Issue 4, 2014, Pages 309-315

  Filippov, Sergey ^a   Pinkosky, Stephen L ^a   Newton, Roger S ^a  

^a Esperion Therapeutics Inc   (United States)

Author keywords

adenosine monophosphate activated protein kinase; adenosine triphosphate citrate lyase; ETC 1002 (8 hydroxy 2,2,14,14 tetramethylpentadecanedioic acid); LDL cholesterol; statin intolerance

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; C REACTIVE PROTEIN; ETC 1002; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYASE INHIBITOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; BODY WEIGHT; CLINICAL EVALUATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEAKNESS;

EID: 84904207540     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000091     Document Type: Review

References (52)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013; 127:e6-e245.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011; 123:933-944.
3. Lewis SJ. Lipid-lowering therapy: Who can benefit? Vasc Health Risk Manag 2011; 7:525-534.
4. Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013; 40:195-211.
5. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368:2004-2013.
6. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: From mice to humans. Immunity 2013; 38:1092-1104.
7. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6:208-215.
8. Maningat P, Breslow JL. Needed: Pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011; 365:2250-2251.
9. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86:304-314.
10. FDA Expands Advice on Statin Risks. http://www.fda.gov/forconsumers/ consumerupdates/ucm293330.htm; 2014.
11. Filippov S, Pinkosky SL, Lister RJ, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res 2013; 54:2095-2108.
12. Pinkosky SL, Filippov S, Srivastava AR, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002-a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 2013; 54:134-151.
13. Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013; 62:1154-1162.
14. Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014; 34:676-683.
15. Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs. Eur Heart J 2013; 34:1783-1789.
16. Kane JP. New horizons in lipid management. J Am Coll Cardiol 2013; 62:1163-1164.
17. Elshourbagy NA, Near JC, Kmetz PJ, et al. Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. J Biol Chem 1990; 265:1430-1435.
18. Pearce NJ, Yates JW, Berkhout TA, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J 1998; 334 (Pt 1):113-119.
19. Chu KY, Lin Y, Hendel A, et al. ATP-citrate lyase reduction mediates palmitateinduced apoptosis in pancreatic beta cells. J Biol Chem 2010; 285:32606-32615.
20. Gribble AD, Ife RJ, Shaw A, et al. ATP-citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega- substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo. J Med Chem 1998; 41:3582-3595.
21. Kanao T, Fukui T, Atomi H, Imanaka T. Kinetic and biochemical analyses on the reaction mechanism of a bacterial ATP-citrate lyase. Eur J Biochem 2002; 269:3409-3416.
22. Lim K, Ryu S, Suh H, et al. (-)-Hydroxycitrate ingestion and endurance exercise performance. J Nutr Sci Vitaminol (Tokyo) 2005; 51:1-7.
23. Melnick JZ, Srere PA, Elshourbagy NA, et al. Adenosine triphosphate citrate lyase mediates hypocitraturia in rats. J Clin Invest 1996; 98:2381-2387.
24. Kim KS, Kang JG, Moon YA, et al. Regulation of ATP-citrate lyase gene transcription. Yonsei Med J 1996; 37:214-224.
25. Park SW, Kim KS, Whang SK, et al. Induction of hepatic ATP-citrate lyase by insulin in diabetic rat-effects of insulin on the contents of enzyme and its mRNA in cytosol, and the transcriptional activity in nuclei. Yonsei Med J 1994; 35:25-33.
26. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
27. Fonarow GC, Watson KE. Effective strategies for long-term statin use. Am J Cardiol 2003; 92:27i-34i.
28. Kastelein JJ. The future of lipid-lowering therapy: The big picture. Neth J Med 2003; 61:35-39.
29. Kovanen PT, Bilheimer DW, Goldstein JL, et al. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 1981; 78:1194-1198.
30. Berkhout TA, Havekes LM, Pearce NJ, Groot PH. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J 1990; 272:181-186.
31. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009; 89:1025-1078.
32. Hardie DG. AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8:774-785.
33. Steinberg GR, Macaulay SL, Febbraio MA, Kemp BE. AMP-activated protein kinase-the fat controller of the energy railroad. Can J Physiol Pharmacol 2006; 84:655-665.
34. Carlson CA, Kim KH. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem 1973; 248:378-380.
35. Saggerson D. Malonyl-CoA, a key signaling molecule in mammalian cells. Annu Rev Nutr 2008; 28:253-272.
36. Beg ZH, Stonik JA, Brewer HB Jr. Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: A review. Metabolism 1987; 36:900-917.
37. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005; 1:361-370.
38. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001; 413:131-138.
39. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423:550-555.
40. Leclerc I, Lenzner C, Gourdon L, et al. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 2001; 50:1515-1521.
41. Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem 2003; 278:27495-27501.
42. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307:384-387.
43. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013; 493:346-355.
44. Liu TF, Brown CM, El Gazzar M, et al. Fueling the flame: Bioenergy couples metabolism and inflammation. J Leukoc Biol 2012; 92:499-507.
45. Blagih J, Krawczyk CM, Jones RG. LKB1 and AMPK: Central regulators of lymphocyte metabolism and function. Immunol Rev 2012; 249:59-71.
46. Fullerton MD, Steinberg GR, Schertzer JD. Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 2012; 366:224-234.
47. Mounier R, Theret M, Arnold L, et al. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab 2013; 18:251-264.
48. Galic S, Fullerton MD, Schertzer JD, et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest 2011; 121:4903-4915.
49. Carroll KC, Viollet B, Suttles J. AMPKalpha1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J Leukoc Biol 2013; 94:1113-1121.
50. Kauppinen A, Suuronen T, Ojala J, et al. Antagonistic crosstalk between NFkappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 2013; 25:1939-1948.
51. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: Impact on healthspan and lifespan. J Mol Med (Berl) 2011; 89:667-676.
52. Cramer CT, Goetz B, Hopson KL, et al. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res 2004; 45:1289-1301.